Minerva Neurosciences logo
Minerva Neurosciences NERV
$ 4.37 0.45%
report update icon

Quarterly report 2026-Q2
added 08-07-2026

Minerva Neurosciences Cash Flow 2025-2011 | NERV

Brief cash flow overview of Minerva Neurosciences

Cash flows are assessed across five available annual periods spanning 2021 to 2025.

The latest year produced an operating outflow of -$13.5 million. A return to positive cash generation is important.

Operating cash flow was positive in only 0 of five periods. Cash generation remains unstable.

What the cash flows show

Minerva Neurosciences has limited cash flow resilience; a return to stable positive cash generation is the main condition for improvement.

Annual Cash Flow Minerva Neurosciences

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Operating Cash Flow

-13.5 M -19.6 M -14.8 M -24.6 M -24.6 M -33.8 M -43.4 M -41.9 M 3.09 M - - - - - -

Depreciation & Amortization

5.44 K 5.44 K 5.44 K - - 16 K 17.5 K 17.5 K 11.1 K 16.5 K 17.3 K 33.9 K - - -

Accounts Payables

640 K 1.61 M 1.81 M 970 K 1.85 M 996 K 2.32 M 1.8 M 1.44 M 1.47 M 1.36 M 642 K - - -

All numbers in USD currency

Quarterly Cash Flow Minerva Neurosciences

2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Operating Cash Flow

-18.8 M -5.43 M - - - -4.07 M - - - -6.09 M - - - -115 K - -20.5 M -11 M -5.81 M - -19.8 M -11.1 M -5.22 M - -26.7 M -16.8 M -9.2 M - -29.3 M -19.7 M -9.6 M - -32.1 M -22.2 M -10.9 M - 12 M -12.9 M - - - - - - - - - - - - - - - - - - - - - - - - -

Depreciation & Amortization

2.72 K - - - - 1.36 K - - - 1.36 K - - - 1.36 K - - - - - - - - - 13.1 K 8.73 K 4.37 K - 13.1 K 8.73 K 4.37 K - 13.1 K 8.73 K 4.37 K - 9.31 K 6.6 K 3.3 K - 13 K 8.64 K 4.32 K - 13 K 8.64 K 9.71 K - 29.9 K 4.27 K 270 - - - - - - - - - - - -

Accounts Payables

1.45 M 2.12 M 640 K 944 K 897 K 640 K 1.61 M 553 K 828 K 1.44 M 1.81 M 1.4 M 298 K 961 K 970 K 533 K 1.52 M 1.59 M 1.85 M 1.2 M 1.59 M 1.13 M 996 K 996 K 996 K 996 K 2.32 M 2.32 M 2.32 M 2.32 M 1.8 M 1.8 M 1.8 M 1.8 M 1.44 M 1.44 M 1.44 M 1.44 M 1.47 M 1.47 M 1.47 M 1.47 M 1.36 M 1.36 M 1.36 M 1.36 M 642 K 642 K 642 K 642 K 523 K 523 K 523 K - - - - - - - - -

All numbers in USD currency

Cash Flow Statement is one of the three key financial reports of the company Minerva Neurosciences, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Biotechnology sector

Issuer Price % 24h Market Cap Country
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Amryt Pharma plc Amryt Pharma plc
AMYT
- - $ 621 M britainBritain
ASLAN Pharmaceuticals Limited ASLAN Pharmaceuticals Limited
ASLN
- -14.27 % $ 1.7 M singaporeSingapore
Revolution Medicines Revolution Medicines
RVMD
$ 207.32 0.24 % $ 39.4 B usaUSA
Rhythm Pharmaceuticals Rhythm Pharmaceuticals
RYTM
$ 101.8 0.08 % $ 6.62 B usaUSA
Rezolute Rezolute
RZLT
$ 4.4 0.88 % $ 334 M usaUSA
Sana Biotechnology Sana Biotechnology
SANA
$ 3.45 0.77 % $ 874 M usaUSA
Seer Seer
SEER
$ 1.95 0.26 % $ 108 M usaUSA
Precigen Precigen
PGEN
$ 6.87 0.14 % $ 2.15 B usaUSA
SIGA Technologies SIGA Technologies
SIGA
$ 3.2 1.86 % $ 229 M usaUSA
Syndax Pharmaceuticals Syndax Pharmaceuticals
SNDX
$ 19.94 0.05 % $ 1.73 B usaUSA
Soligenix Soligenix
SNGX
$ 0.38 1.18 % $ 1.97 M usaUSA
Spruce Biosciences Spruce Biosciences
SPRB
$ 59.09 2.0 % $ 45.3 M usaUSA
Sarepta Therapeutics Sarepta Therapeutics
SRPT
$ 20.94 0.04 % $ 2.1 B usaUSA
Stoke Therapeutics Stoke Therapeutics
STOK
$ 30.05 0.81 % $ 1.78 B usaUSA
Sutro Biopharma Sutro Biopharma
STRO
$ 19.1 0.34 % $ 162 M usaUSA
Shattuck Labs Shattuck Labs
STTK
$ 6.5 0.29 % $ 452 M usaUSA
Supernus Pharmaceuticals Supernus Pharmaceuticals
SUPN
$ 42.43 0.23 % $ 2.4 B usaUSA
Savara Savara
SVRA
$ 5.53 2.98 % $ 1.23 B usaUSA
China SXT Pharmaceuticals China SXT Pharmaceuticals
SXTC
$ 2.24 0.45 % $ 1.52 M chinaChina
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
TAK
$ 18.32 1.49 % $ 28.9 B japanJapan
Bio-Techne Corporation Bio-Techne Corporation
TECH
$ 72.31 0.01 % $ 11.3 B usaUSA
Tenax Therapeutics Tenax Therapeutics
TENX
$ 1.98 2.06 % $ 77.7 M usaUSA
Teva Pharmaceutical Industries Limited Teva Pharmaceutical Industries Limited
TEVA
$ 36.76 1.21 % $ 42.1 B israelIsrael
TG Therapeutics TG Therapeutics
TGTX
$ 55.74 0.58 % $ 8.04 B usaUSA
Trevi Therapeutics Trevi Therapeutics
TRVI
$ 16.82 1.17 % $ 2.27 B usaUSA
Taysha Gene Therapies Taysha Gene Therapies
TSHA
$ 5.48 0.54 % $ 1.75 B usaUSA
Sol-Gel Technologies Ltd. Sol-Gel Technologies Ltd.
SLGL
$ 69.37 0.35 % $ 193 M israelIsrael
UroGen Pharma Ltd. UroGen Pharma Ltd.
URGN
$ 43.82 0.02 % $ 2.11 B israelIsrael
United Therapeutics Corporation United Therapeutics Corporation
UTHR
$ 497.97 2.12 % $ 22.1 B usaUSA
Spero Therapeutics Spero Therapeutics
SPRO
$ 1.19 0.41 % $ 66.7 M usaUSA
Scholar Rock Holding Corporation Scholar Rock Holding Corporation
SRRK
$ 57.42 3.78 % $ 6.59 B usaUSA
Jounce Therapeutics Jounce Therapeutics
JNCE
- - $ 98.4 M usaUSA
NextCure NextCure
NXTC
$ 8.42 7.67 % $ 23.9 M usaUSA
Verrica Pharmaceuticals Verrica Pharmaceuticals
VRCA
$ 5.26 0.75 % $ 56 M usaUSA
Viridian Therapeutics Viridian Therapeutics
VRDN
$ 23.17 1.09 % $ 2.36 B usaUSA
Zosano Pharma Corporation Zosano Pharma Corporation
ZSAN
- 7.23 % $ 2.72 M usaUSA
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
VRTX
$ 528.9 0.22 % $ 135 B usaUSA
Verastem Verastem
VSTM
$ 8.08 0.55 % $ 560 M usaUSA
vTv Therapeutics vTv Therapeutics
VTVT
$ 32.79 0.03 % $ 130 M usaUSA
Voyager Therapeutics Voyager Therapeutics
VYGR
$ 3.4 3.85 % $ 200 M usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Wave Life Sciences Ltd. Wave Life Sciences Ltd.
WVE
$ 4.91 1.03 % $ 828 M singaporeSingapore
Tonix Pharmaceuticals Holding Corp. Tonix Pharmaceuticals Holding Corp.
TNXP
$ 13.16 0.15 % $ 112 M usaUSA
Xenetic Biosciences Xenetic Biosciences
XBIO
$ 4.28 0.86 % $ 7.28 M usaUSA
XBiotech XBiotech
XBIT
$ 2.18 0.23 % $ 66.5 M usaUSA
Exicure Exicure
XCUR
$ 1.41 12.8 % $ 8.88 M usaUSA
Xenon Pharmaceuticals Xenon Pharmaceuticals
XENE
$ 59.55 0.18 % $ 4.72 B canadaCanada
Xeris Pharmaceuticals Xeris Pharmaceuticals
XERS
$ 8.48 0.12 % $ 1.36 B usaUSA